ESR1 and breast cancer: In addition to the HR+, HER2– high-risk BC patient population, triple-negative BC (ER–, PR–, HER2–)(TNBC) represents a highly aggressive type of BC characterized by poorer prognosis and an unmet medical need for improving adjuvant systemic therapy.30,31